References
- Burningham Z, Hashibe M, Spector L, et al. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2:14.
- Howlader N, Noone AM, Krapcho M, et al. Seer cancer statistics review, 1975–2013. Based on November 2015 SEER data submission, posted to the SEER web site, April 2016
- Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2011;117:1049–1054.
- Liebner DA. The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J Surg Oncol. 2015;111:622–631.
- Boucek RJ Jr., Olson RD, Brenner DE, et al. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem. 1987;262:15851–15856.
- Lorigan P, Verweij J, Papai Z, et al. Phase iii trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation For Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol. 2007;25:3144–3150.
- Van Der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (palette): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–1886.
- Demetri GD, Von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase iii randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–793.
- Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–1637.
- Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388:488–497.
- O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin hcl (caelyx/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncology: Official J Eur Soc Med Oncol. 2004;15:440–449.
- Judson I, Radford JA, Harris M, et al. Randomised phase ii trial of pegylated liposomal doxorubicin (doxil/caelyx) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the eortc soft tissue and bone sarcoma group. Eur J Cancer. 2001;37:870–877.
- Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the epr effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284.
- Kratz F. Doxo-emch (inno-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs. 2007;16:855–866.
- Kratz F, Warnecke A, Scheuermann K, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem. 2002;45:5523–5533.
- Unger C, Haring B, Medinger M, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res. 2007;13:4858–4866.
- Mita MM, Natale RB, Wolin EM, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs. 2015;33:341–348.
- Chawla SP, Chua VS, Hendifar AF, et al. A phase 1b/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015;121:570–579.
- Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncology. 2015;1:1272–1280.
- Chawla SP GK, Schuetze S, et al. Phase iii study of aldoxorubicin vs. investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. J Clin Oncol. 2017;35(suppl):abstr 11000.